Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 17/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834836 | 0.93 | NAMPT (0.58) | NAMPTCYP3A4CYP2C9CDK2FLT4 | |
| SCHEMBL31596799 | 0.88 | NAMPT (0.51) | NAMPTCYP3A4CYP2C9 | |
| SCHEMBL25642250 | 0.88 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9CDK2FLT4 | |
| SCHEMBL25643926 | 0.88 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9CDK2FLT4 | |
| SCHEMBL25223204 | 0.88 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9CDK2FLT4 | |
| SCHEMBL25228399 | 0.88 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9CDK2FLT4 | |
| SCHEMBL25643875 | 0.88 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9CDK2FLT4 | |
| SCHEMBL25642286 | 0.88 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9CDK2FLT4 | |
| SCHEMBL31596955 | 0.87 | NAMPT (0.51) | NAMPTCYP3A4CYP2C9 | |
| SCHEMBL19834806 | 0.85 | NAMPT (0.46) | NAMPTCYP3A4CYP2C9CDK2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109097-A2 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | NAMPT, NAPRT, NNMT | NAMPT 1/4885CYP3A4 3597/4885CYP2C9 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.